Korea To Bolster Fast-Track System With Speedier Approvals In Mind
This article was originally published in PharmAsia News
With a broad ambition to improve the global competitiveness of its biopharma industry, South Korea is steadily unveiling supportive regulatory measures. Among the planned steps this year are the strengthening and clarification of an existing fast-track review and approval system, although the government says a limited number of reviewers may hamper the improved handling of such evaluations.
You may also be interested in...
Roche, GSK Face Compulsory Licensing Of Antivirals If Swine Flu Emergency Hits - South Korean Health Minister
After probing pharmacokinetic data flaws in the first US Phase III study for its gene therapy Engensis, Korea's Helixmith concludes that these stemmed from clinical operation issues. As a result, it admits a failure to meet the primary endpoint but is still moving forward with new trials given signals of efficacy and safety in an extended study.
Deal news from Strides Pharma, Pharmaceutics Intl., Cipla, Wanbury, AstraZeneca, Syntekabio, Arctoris, Mundipharma, Samsung Bioepis…